The Impact of Telemonitoring on Improving Glycemic and Metabolic Control in Previously Lost-to-Follow-Up Patients with Type 2 Diabetes Mellitus: A Single-Center Interventional Study in the United Arab Emirates

• Published in: International journal of clinical practice (Esher) Vol. 2022; pp. 6286574 - 9
• Main Authors: Farooqi, Muhammad Hamed, Abdelmannan, Dima Kamal, Al buflasa, Manal Mubarak, Abbas Hamed, Moataz Abdalla, Xavier, Maxon, Santos Cadiz, Tessa Joyce, Nawaz, Faisal Amir
• Format: Journal Article
• Language: English
• Published: India Hindawi 2022; Hindawi Limited
• Subjects: Blood glucose; Body weight; Cellular telephones; Chronic illnesses; Coronaviruses; COVID-19; Demographics; Diabetes; Diabetes mellitus (non-insulin dependent); Disease; Electrocardiography; Glucose; Hemoglobin; Hypertension; Medical history; Patients; Telemedicine; Urine; Vital signs; Middle East; Dubai United Arab Emirates; United Arab Emirates
• DOI: 10.1155/2022/6286574
• EISSN: 1742-1241
• ISSN: 1368-5031

Background. Telemonitoring (TM), mobile-phone technology for health, and bluetooth-enabled self-monitoring devices represent innovative solutions for proper glycemic control, compliance and monitoring, and access to providers. Objective. In this study, we evaluated the impact of TM devices on glycemic control and the compliance of 38 previously lost-to-follow-up (LTFU) patients with type 2 diabetes mellitus (T2DM). Methods. This was an interventional single-center study that randomly recruited LTFU patients from the Dubai Diabetes Center (DDC), UAE. After contact and recruitment by phone, patients had an initial visit at which they were provided with home-based TM devices. A follow-up visit was conducted three months later. Results. The mean HbA1c decreased significantly from 10.3 ± 1.9% at baseline to 7.4 ± 1.5% at the end of follow-up, with a mean difference (MD) of −2.9% [95% CI: −3.6 to −2.2]. The percentage of patients with HbA1c <7% was 50% after three months. Home-based blood sugar monitor devices showed a significant reduction in fasting blood glucose (FBG) after three months (MD = -40.1 mg/dL, 95% CI: −70.8 to −9.3). A significant reduction was observed in terms of body weight after three months (MD = −1.3 kg, 95% CI: −2.5 to −0.08). The mean number of days the participants used a device was the highest for portable pill dispensers (86.5 ± 22.8 days), followed by a OneTouch® blood glucose monitor (72.9 ± 23.5 days). Conclusions. TM led to significant improvements in overall diabetes outcomes, including glycemic control and body weight, indicating its effectiveness in a challenging population of T2DM patients who had previously been lost to follow-up.